ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
Belite Bio Inc

Belite Bio Inc (BLTE)

69.71
-0.19
(-0.27%)
종가: 05 11월 6:00AM
69.71
0.00
( 0.00% )
시간외 거래: 6:30AM

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

주요 통계 및 세부정보

가격
69.71
매수가
68.01
매도가
73.56
거래량
165,510
62.33 일간 변동폭 70.90
0.00 52주 범위 0.00
market_cap
전일 종가
69.90
개장가
69.90
최근 거래 시간
280
@
69.71
마지막 거래 시간
06:00:00
재정 규모
US$ 11,446,373
VWAP
69.1582
평균 볼륨(3m)
-
발행 주식
29,149,444
배당수익률
-
주가수익률
0.00
주당순이익(EPS)
-
매출
-
순이익
-31.63M

Belite Bio Inc 정보

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressiv... Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
본부
Grand Cayman, Cym
설립됨
-
Belite Bio Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker BLTE. The last closing price for Belite Bio was US$69.90. Over the last year, Belite Bio shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Belite Bio currently has 29,149,444 shares in issue. The market capitalisation of Belite Bio is US$2.04 billion.

BLTE 최신 뉴스

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing...

Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel...

Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Deutsche Bank Depositary...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
SPPLSIMPPLE Ltd
US$ 1.6603
(40.70%)
17.92M
QNSTQuinStreet Inc
US$ 25.95
(28.47%)
35.18k
BCOVBrightcove Inc
US$ 2.74
(28.04%)
354.57k
PTIRGraniteShares 2X Long PLTR Daily ETF
US$ 55.80
(27.66%)
99.12k
BNOXBionomics Ltd
US$ 0.239
(24.97%)
8.38M
MQMarqeta Inc
US$ 4.08
(-31.43%)
2.94M
FAASDigiAsia Corporation
US$ 0.70
(-22.22%)
29.86k
VRCAVerrica Parmaceuticals Inc
US$ 1.12
(-21.68%)
103.09k
LSCCLattice Semiconductor Corp
US$ 42.47
(-18.15%)
418.88k
NVTSNavitas Semiconductor Corporation
US$ 2.1599
(-17.25%)
1.34M
ELABElevai Labs Inc
US$ 0.0239
(18.91%)
26.54M
SPPLSIMPPLE Ltd
US$ 1.6603
(40.70%)
17.92M
IDAIT Stamp Inc
US$ 0.2444
(-0.24%)
15.27M
BNOXBionomics Ltd
US$ 0.239
(24.97%)
8.38M
NVDANVIDIA Corporation
US$ 135.98
(-0.05%)
5.07M

BLTE Discussion

게시물 보기
Monksdream Monksdream 2 월 전
BLTE will it break out
👍️0
conix conix 2 년 전
Short Interest for BLTE--Up 30%

https://www.etfdailynews.com/2022/09/17/short-interest-in-belite-bio-inc-nasdaqblte-expands-by-30-1/
👍️0
conix conix 2 년 전
BLTE News

https://seekingalpha.com/news/3875434-blte-stock-gains-as-pivotal-trial-for-lead-asset-starts-in-us
👍️0
conix conix 2 년 전
'Novel Approach For Retinal Disease Needs' Stock Belite Bio Has 70% Potential Upside According To This Analyst

Vandana Singh

Mon, August 1, 2022

HC Wainwright initiated coverage on Belite Bio Inc (NASDAQ: BLTE) with a Buy rating and price target of $58 per ADS.

Belite Bio is focused on developing a novel once-daily oral drug for the treatment of Stargardt disease (STGD1)—a rare inherited juvenile-onset form of macular degeneration.

The lead drug candidate is LBS-008 (or Tinlarebant).

HC Wainwright says that as LBS-008 is administered orally once a day, it could be adopted rapidly by ophthalmologists and patients once the drug obtains regulatory approval, as the intravitreal injection procedure was found unpleasant.

"We believe LBS-008 has the potential to be developed as the first and best-in-class oral drug for the treatment of STGD1," the analyst writes.

The analyst expects the Phase 2 portion to report 1-year data in 2H22.

Meanwhile, the company has initiated a Phase 3 trial of LBS-008 in adolescent STGD1 in 1H22, slated to enroll approximately 60 patients. Enrollment for Phase 3 trial to complete in mid-2023.
👍️0
conix conix 3 년 전
Belite Bio stock soars 65% in wake of strong IPO performance

May 03, 2022 12:30 PM ETBLTEBy: Val Kennedy, SA News Editor

IPO Initial Public Offering

Mikko Lemola/iStock via Getty Images

Belite Bio (BLTE) stock soared 65% on Tuesday on the heels of a strong performance last Friday following its $36M initial public offering.

Shares of the ophthalmology drug developer opened at $10.60, recently changing hands at $14.70, up 65%, at approximately $12.05 p.m. ET.

BLTE held its IPO on April 29, offering 6 million American Depositary Shares at $6 per ADS. Underwriters were granted an option to buy up to 900k additional shares ADSs at the public price. The company’s principal stockholder, Taiwan’s Lin BioScience, agreed to buy around $15M of the offering.

The stock rocketed following the IPO on Friday, reaching a session high of $17.50 before closing at $10.59, up 77% over its offering price. The stock slid 16% on Monday.

BLTE has been focused on developing treatments for eye and metabolic diseases. The company plans to use proceeds from the IPO in part to fund Phase 3 clinical testing for its drug candidate LBS-008 for Stargardt disease and further development of the product for the treatment of dry age-related macular degeneration.
👍️0
conix conix 3 년 전
Great news

https://www.morningstar.com/news/dow-jones/202205038965/belite-bio-shares-jump-47-after-fast-track-designation-for-lbs-008-treatment-for-stargardt-disease
👍️0

최근 히스토리

Delayed Upgrade Clock